Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Tranexamic acid
Ibigen Srl
B02AA; B02AA02
Tranexamic acid
100 milligram(s)/millilitre
Solution for injection/infusion
Product subject to prescription which may not be renewed (A)
Amino acids; tranexamic acid
Marketed
2014-12-05
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TRANEXAMIC ACID 100 MG/ML, SOLUTION FOR INJECTION/INFUSION tranexamic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor or nurse • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tranexamic Acid is and what it is used for 2. What you need to know before you are given Tranexamic Acid 3. How to take Tranexamic Acid 4. Possible side effects 5. How to store Tranexamic Acid 6. Contents of the pack and other information 1. WHAT TRANEXAMIC ACID IS AND WHAT IT IS USED FOR Tranexamic Acid Solution for Injection/Infusion contains tranexamic acid which belongs to a group of medicines called ‘anti-haemorrhagics’ or ‘anti-fibrinolytics’. Tranexamic Acid is used in adults and children above one year of age for the prevention and treatment of bleeding which is caused by a process that inhibits blood clotting called fibrinolysis. Specific indications include: • heavy periods in women • gastrointestinal bleeding • haemorrhagic urinary disorders, after having an operation on your prostate gland or urinary tract • after having an operation on your ear, nose or throat • after having heart, abdominal or gynaecological surgery • bleeding after you have been treated with another medicine to treat blood clots 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN TRANEXAMIC ACID DO NOT TAKE TRANEXAMIC ACID IF YOU: • are allergic to tranexamic acid or any of the other ingredients of this medicine (listed in section 6) • currently have a blood clot(s) or have every had a disease leading to blood clots. (If you are at risk of having blood clots, see ‘Warnings and precautions’ below) • have a condition called ‘consumption coagulopathy’ where blood in the whole body Read the complete document
Health Products Regulatory Authority 30 January 2020 CRN009JGD Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tranexamic Acid 100 mg/ml solution for injection/infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of solution contains 100 mg of tranexamic acid. Each 5 ml of solution contains 500 mg of tranexamic acid. Each 10 ml of solution contains 1 g of tranexamic acid. Excipient with known effect: Contains less than 1mmol sodium per dose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection/infusion Clear solution free of particles in a colourless glass ampoule. pH 6.5 - 8.0 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year. Specific indications include: ● Haemorrhage caused by general or local fibrinolysis such as: ● Menorrhagia and metrorrhagia ● Gastrointestinal bleeding ● Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract ● Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions) ● Gynaecological surgery or disorders of obstetric origin ● Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery ● Management of haemorrhage due to the administration of a fibrinolytic agent 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ Unless otherwise prescribed, the following doses are recommended: 1. Standard treatment of local fibrinolysis: 0.5 g (1 ampoule of 5 ml) to 1 g (1 ampoule of 10 ml or 2 ampoules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) two to three times daily 2. Standard treatment of general fibrinolysis: 1 g (1 ampoule of 10 ml or 2 ampoules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW _ _ _Patients with renal impairment_ In renal insufficiency leading to a risk of acc Read the complete document